The FDA has cleared a next-generation system to continuously monitor patients’ blood pressure while they’re undergoing surgery without the use of inflatable cuffs or invasive arterial catheters.
Maryland Urologist, Founder of Perineologic Develops Safe Approach to Prostate Cancer Biopsy
For the past 30 years, screening for prostate-specific antigen (PSA) levels has been the gold standard for screening of prostate cancer. When high levels are found, physicians typically turn to a diagnostic biopsy using a transrectal route. However, a Maryland urologist has developed a different approach through the perineum, the strip of skin between the rectum and scrotum that is safer and more effective.
How to Partner with the Frederick National Lab and National Cancer Institute
Both the FNL and NCI look for partnerships that can aid their work while providing their partners’ resources and expertise. The lab’s partners often include big pharmaceutical and biotech companies that are more product-driven than NCI and FNL, which are more research-driven.
5 Questions with Sue Carr, RPh, President and Founder, CarrTech, LLC
Sue Carr RPh is President and Founder of CarrTech LLC, a medical device company. CarrTech has developed, patented, and prototyped an all-in-one package one needle filter device to increase safety and compliance while reducing time and waste. CarrTech’s mission is to improve healthcare by making medication preparation safer.
Baltimore’s Personal Genome Diagnostics Secures $103 Million in Financing
Cancer genomics company Personal Genome Diagnostics Inc. (PGDx) secured $103 million in a Series C financing round. Proceeds from the financial infusion will be used to expand the company’s tissue-based and liquid biopsy portfolio and its global commercial footprint to support growth.
Aurinia Wins FDA Approval for First LN Oral Drug
The FDA greenlit Aurinia’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen for LN, a serious progression of systemic lupus erythematosus (SLE), a chronic, complex and autoimmune disease. The approval not only marks the first medication in the United States specifically approved for active LN, it also marks the first for Aurinia, which is headquartered in Canada and last year opened its 30,000 square-foot commercialization facility in the BioHealth Capital Region.
Viela Bio’s Uplizna Granted FDA Approval As Company’s First Commercial Product
Viela Bio’s Uplizna™ Granted FDA Approval As Company’s First Commercial Product Viela Bio’s Uplizna™ (inebilizumab-cdon), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMOSD), was approved by the [….]
Two Frederick, Maryland MedTech Companies Receive FDA 510K Approvals
Two Frederick, Maryland MedTech Companies Receive FDA 510K Approvals August 13, 2019 Frederick County, Maryland continues to be a vibrant hub for growing bioscience organizations. With its robust life science [….]
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, [….]
Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™
Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™ November 20, 2018 Leadiant Biosciences, Inc. formerly known as Sigma-Tau Pharmaceuticals, recently received FDA approval for Revcovi™, which [….]